FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied

Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed